MARKET

PTGX

PTGX

Protagonist
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.00
-0.29
-1.78%
Opening 14:06 07/13 EDT
OPEN
16.31
PREV CLOSE
16.29
HIGH
16.40
LOW
15.93
VOLUME
348.74K
TURNOVER
--
52 WEEK HIGH
19.67
52 WEEK LOW
4.470
MARKET CAP
550.96M
P/E (TTM)
-5.0795
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTGX stock price target is 27.50 with a high estimate of 33.00 and a low estimate of 19.00.

EPS

PTGX News

More
Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?
Insider Monkey · 06/28 02:27
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Why Protagonist Should Be On Your Radar After Latest Trial Update
Seeking Alpha - Article · 06/26 07:49
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
Zacks · 06/18 15:23
Protagonist Therapeutics Announces Hepcidin Mimetic PTG-300 Receives FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera.
Benzinga · 06/18 09:54
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
PR Newswire · 06/18 04:07
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference
PR Newswire · 06/16 23:05
Edited Transcript of PTGX.OQ earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/16 00:06

Industry

Biotechnology & Medical Research
+1.59%
Pharmaceuticals & Medical Research
+1.78%

Hot Stocks

Symbol
Price
%Change

About PTGX

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
More

Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.